Shares of PDS Biotechnology Corporation (NASDAQ:PDSB - Get Free Report) shot up 8.7% during trading on Wednesday . The company traded as high as $1.25 and last traded at $1.25. 709,500 shares were traded during mid-day trading, an increase of 49% from the average session volume of 477,041 shares. The stock had previously closed at $1.15.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the company. Wall Street Zen cut PDS Biotechnology from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. HC Wainwright restated a "buy" rating and issued a $13.00 price target on shares of PDS Biotechnology in a research note on Tuesday, July 1st.
Read Our Latest Research Report on PDS Biotechnology
PDS Biotechnology Stock Down 3.2%
The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of 0.29. The firm's 50 day simple moving average is $1.44 and its two-hundred day simple moving average is $1.36. The firm has a market cap of $55.31 million, a price-to-earnings ratio of -1.29 and a beta of 1.21.
PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. On average, equities analysts forecast that PDS Biotechnology Corporation will post -1.2 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Raymond James Financial Inc. bought a new stake in PDS Biotechnology during the 4th quarter valued at $26,000. Jane Street Group LLC purchased a new stake in PDS Biotechnology in the 4th quarter valued at $58,000. Marshall Wace LLP raised its position in PDS Biotechnology by 38.4% in the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company's stock valued at $64,000 after buying an additional 10,837 shares during the last quarter. Tempus Wealth Planning LLC grew its position in PDS Biotechnology by 154.3% during the second quarter. Tempus Wealth Planning LLC now owns 47,800 shares of the company's stock valued at $64,000 after buying an additional 29,000 shares during the period. Finally, Iron Gate Global Advisors LLC bought a new position in PDS Biotechnology during the first quarter valued at about $89,000. Institutional investors and hedge funds own 26.84% of the company's stock.
About PDS Biotechnology
(
Get Free Report)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
Featured Articles
Before you consider PDS Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PDS Biotechnology wasn't on the list.
While PDS Biotechnology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
